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rug-Eluting Stent Thrombosis
he Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
ack P. Chen, MD,* Dongming Hou, MD, PHD,* Lakshmana Pendyala, MD,*
ohn A. Goudevenos, MD, PHD,† Nicholas G. Kounis, MD, PHD‡
tlanta, Georgia; and Ioannina and Patras, Greece
he advent of drug-eluting stents (DES) has revolutionized the ﬁeld of interventional cardiology. Their
ramatic and persistent restenotic and target lesion revascularization advantages are unquestioned.
owever, concerns over the rare but potentially catastrophic risk of stent thrombosis (ST) have tem-
ered universal acceptance of these devices. Although the precise mechanism of DES ST is undoubt-
dly multifactorial and as yet not fully elucidated, delayed or incomplete endothelial healing clearly
lays a pivotal role. Detailed histopathological data have implicated a contributory allergic or hyper-
ensitivity component, as veriﬁed by the Food and Drug Administration’s Manufacturer and User De-
ice Experience Center and the Research on Adverse Drug/device events And Reports (RADAR) project.
hese ﬁndings thus suggest a potential connection with the Kounis syndrome, the concurrence of
cute coronary events with allergic, hypersensitivity, anaphylactic, or anaphylactoid reactions. Potential
ulprits responsible for this phenomenon include: arachidonic acid metabolites such as leukotrienes
nd thromboxane, proteolytic enzymes such as chymase and tryptase, histamine, cytokines, and che-
okines. Additionally, inﬂammatory cells such as macrophages, T-lymphocytes, and mast cells are
robably also contributory. Autopsy-conﬁrmed inﬁltrates of various inﬂammatory cells including lym-
hocytes, plasma cells, macrophages, and eosinophils have been reported in all 3 vascular wall layers
nd are reminiscent of those associated with the Kounis syndrome. Although the concurrence of acute
oronary syndromes with hypersensitivity reactions has been long established, the speciﬁc association
ith DES ST remains unproven. Potential incorporation of hypersensitivity suppressive agents might
epresent a promising paradigm shift from efﬁcacy to safety in future DES designs. (J Am Coll Cardiol
ntv 2009;2:583–93) © 2009 by the American College of Cardiology Foundatione
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She advent of drug-eluting stents (DES) has
itnessed dramatic reductions in clinical restenosis
nd the need for target lesion revascularization
TLR) over prior bare-metal counterparts (1,2).
nitial enthusiasm, however, has been tempered by
rowing concerns surrounding risks of late stent
hrombosis (ST) and very late ST. In his address to
he 2006 European Society of Cardiology, Cam-
rom the *Saint Joseph’s Translational Research Institute, Saint Joseph’s
eart and Vascular Institute, Atlanta, Georgia; †Cardiology Depart-
ent, Ioannina University Medical School, Ioannina, Greece; and
Medical Sciences, Patras Highest Institute of Education and Technol-
gy, Patras, Greece. Sotirios Tsimikas, MD, served as Guest Editor for
his paper.E
anuscript received March 11, 2009; revised manuscript received March
0, 2009, accepted April 7, 2009.nzind (3) reported a significantly higher 6.3%
ombined death/myocardial infarction (MI) rate of
ES over the 3.9% observed for bare-metal stents
BMS). This announcement amplified brewing
oncerns raised by previous isolated reports of DES
ate/very late ST. The Academic Research Con-
ortium (ARC) has further subclassified ST ac-
ording to the timing and relative certainty of the
iagnosis (Table 1) (4).
ES ST
tudies have differed in conclusions regarding
verall DES and BMS thrombosis rates, however.
pecifically, the RESEARCH (Rapamycin-
luting Stent Evaluated At Rotterdam Cardiology
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584ospital) registry reported a 0.4% DES ST rate compared
ith 1.6% for BMS (p  0.10). All events occurred within
0 days of implantation (5). The meta-analysis of 4 of the
AXUS (Boston Scientific, Natick, Massachusetts) ran-
omized trials by Ellis et al. (6) reported similar 3-year
umulative ST rates for DES and BMS patients of 1.28 
.31% and 0.76  0.23%, respectively (p  0.26). Throm-
osis rates from 6 months to 3 years, however, were higher
or DES versus BMS (hazard ratio [HR]: 0.19 vs. 0.02, p
.05). Of note, no patients with DES were receiving
lopidogrel at the time of ST.
The much-publicized BASKET-LATE (Basel Stent
osten Effiktivitats Trial-Late Thrombotic Events) fol-
owed 544 DES and 281 BMS patients for 18 months after
mplantation. The investigators found that DES patients
experienced higher major adverse
cardiovascular event (MACE)
rates from 6 to 18 months. In
particular, there were absolute
excesses in late mortality of 1.2%
(1.2% vs. 0%, p  0.09) and
nonfatal MI of 2.7% (4.1% vs.
1.3%, p  0.04), compared with
BMS. Nonetheless, no differ-
ence in cumulative MACE was
observed, owing to the early
(6-month) benefit conferred
by DES. Two noteworthy issues
should be mentioned. First, dual
antiplatelet therapy (DAT) with
clopidogrel/acetylsalicylic acid
(ASA) was continued for only 6
months in these patients. Addi-
tionally, only those patients free
of events during the initial 6
months were included in the late
follow-up. As expected, a higher
percentage of BMS patients
were thus excluded, introducing
potential bias (7). These findings further underscore the
mportance of adherence to prolonged DAT.
More recent large-scale trials and meta-analyses, how-
ver, have reaffirmed the overall MACE equivalency of
MS and DES during long-term follow-up. From 2002 to
005, the Western Denmark Heart Registry reported per-
utaneous coronary intervention (PCI) data from 12,395
atients who underwent 17,152 stent implantations. A total
f 5,422 and 11,730 lesions received DES and BMS,
espectively. Over the mean follow-up duration of 15
onths, ARC-defined ST was observed in 1.80% and
.15% of BMS and DES patients, respectively. Definite
hrombosis rates were similar between groups, but late ST
eyond 12 months occurred more frequently in the DES
bbreviations
nd Acronyms
RC  Academic Research
onsortium
SA  acetylsalicylic acid
MS  bare-metal stent(s)
AT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
DA  Food and Drug
dministration
R  hazard ratio
g  immunoglobulin
ACE  major adverse
ardiovascular events
I  myocardial infarction
CI  percutaneous
oronary intervention
T  stent thrombosis
LR  target lesion
evascularizationohort (HR: 10.93). Furthermore, the risk of MI after 12 nonths was higher in the DES patients (HR: 4.00).
onetheless, importantly, overall mortality was similar; and
LR was reduced by 43% in the DES group (HR: 0.57) (8).
Additionally, in a recent meta-analysis, Mauri et al. (9)
ooled and analyzed 4-year data from 2,278 DES and 2,267
MS patients, according to ARC criteria. No significant
ntergroup differences were found for overall ST or definite/
robable ST. Specifically, the occurrences of definite/
robable ST from 1 to 4 years were similar.
Although current data demonstrate that overall MI, ST,
ortality, and MACE rates are similar for BMS and DES,
hat of late/very late ST seems slightly higher for DES
0.2% to 0.6%/year beyond the first year). This is counter-
alanced, however, by a 10% to 15% absolute reduction in
LR seen with DES, conferring equivalent or even slightly
uperior MACE rates in most trials and series (10,11). The
resent evidence overwhelmingly supports prolonged DAT.
ccordingly, the current U.S. Food and Drug Administra-
ion’s (FDA) recommendations for DAT are a minimum of
year for DES or 1 month for BMS (4). Tables 2 and 3
ummarize the ST rates in recently published randomized
ontrolled DES trials and registries.
athophysiology of Late ST
he pathophysiology of ST has not been fully elucidated. A
ombination of factors might be involved, including
rocedure-related variables, patient-related issues, and le-
ion characteristics (12–14) (Table 4). In one prospective
bservational study, premature clopidogrel discontinuation
redicted risk of subacute and late ST within 6 months of
eployment but not beyond (14).
Late/very late ST and prevention of in-stent restenosis
ikely represent 2 sides of the double-edged sword of DES
eointimal inhibition. Platelets, when exposed to non-
ndothelialized stent struts, are the key mechanistic trigger
or thrombosis. Initial platelet adhesion results from binding
f von Willebrand’s factor, glycoprotein Ib and Ia/IIa, and
ollagen. Next, activation occurs via release of vasoactive
actors including thrombin, adenosine diphosphate, throm-
oxane A2, and serotonin. Subsequently, activated platelets
re linked into an aggregate meshwork by glycoprotein
Ib/IIIa, serotonin, and fibrinogen. The resultant platelet
lug might acutely progress to thrombotic stent occlusion
15–17). Additionally, experimental models suggest that
nhibition of proliferation and differentiation of human
ndothelial progenitor cells might further impede delayed or
bsent vascular endothelial healing in DES patients. More-
ver, animal DES data have demonstrated significant intra-
ural thrombus formation within the stent lumen as well as
ndothelial dysfunction at both proximal and distal adjacent
onstented segments (18,19) (Figs. 1 and 2).
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585Human autopsy series have suggested that DES late/very
ate ST is partly attributable to impairment of arterial
ealing characterized by incomplete re-endothelialization,
ersistent fibrin deposition, and macrophage infiltration
hen compared with BMS. In a recent necropsy compari-
on of 23 DES with 25 BMS cases, delayed healing
anifested by persistent fibrin deposition and incomplete
e-endothelialization emerged as an important discrimina-
or between BMS and DES. In cases of late/very late ST,
ompared with those of patent DES or BMS, re-
ndothelialization was reduced (27  26% vs. 66  25% vs.
Table 1. Reported Rates of ST in Randomized Controlled Trials and Meta-A
Study (Ref. #) n Study Design
Stent
Type
Antiplatelet
Medication an
Duration
Moreno et al.* 5,030 Meta-analysis: BMS (48%)
SES (17%)
PES (34%)
ASATP (1–6 mon
Bavry et al. (71) 3,817 Meta-analysis:
RCT of
BMS vs.
PES
BMS (48%)
PES (52%)
ASATP (0–6 mon
Kastrati et al.† 3,669 Meta-analysis:
RCT of SES
vs. PES
SES (50%)
PES (50%)
ASATP (2–12 mon
Mauri et al. (9) 4,545 Meta-analysis:
RCT of
BMS vs.
DES
BMS (50%)
SES (19%)
PES (31%)
ASATP (2–6 mon
Pﬁsterer et al.
(BASKET-LATE) (7)
746 RCT of BMS
vs. DES
BMS (38%)
SES (34%)
PES (38%)
ASA
Ellis et al. (6) 3,445 Meta-analysis:
RCT of
BMS vs.
PES
PES (50%)
BMS (50%)
ASATP (6 months
Stone et al. (2) 5,261 Meta-analysis:
RCT of
BMS vs.
DES
BMS (50%)
SES (17%)
PES (33%)
ASATP (2–6 mon
Bavry et al. (10) 6,675 Meta-analysis:
VLST in
RCT of
BMS vs.
DES
BMS (50%)
SES (24%)
PES (26%)
ASA
*Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled a
al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: met
ACS acute coronary syndrome; angio angiography; ARC Academic Research Consortium
Thrombotic Events; BMS bare-metal stent(s); DES drug-eluting stent(s); LST late stent throm
intervention; PES paclitaxel-eluting stent(s); RCT randomized controlled trial; SAT subacute
TP thienopyridines; VLST very late stent thrombosis.0  21%), whereas fibrin scores were increased (3.0  0.9 ys. 1.9 1.1 vs. 0.9 0.8). Endothelial coverage was nearly
omplete in BMS specimens examined beyond 6 months,
hereas incomplete re-endothelialization in DES speci-
ens persisted beyond 40 months. Fourteen of 21 DES
atients suffered late/very late ST, which was related to
elayed healing in all cases (20). The results of this analysis,
owever, might have been confounded by selection bias,
ecause DES patients were more likely to undergo autopsy
or suspected ST, whereas those with BMS were likely
eferred for other reasons.
Mounting reports of DES late/very late ST beyond 1
es
Follow-Up
Duration
(Months) ST Definition ST Rate
6–12 Unspeciﬁed SAT: 0.35% (BMS  DES)
LST: 0.23% (BMS  DES)
6–12 ACSangio SATLST: 0.6% (PES  BMS)
6–13 ACSangio, unexplained
SCD, MI in stented
territory
SATLST: 1.0% (PES  SES)
48 ARC: deﬁniteprobable SES vs. BMS
SAT 0.5% vs. 0.3%
LST 0.1% vs. 1%
VLST 0.9% vs. 0.4%
PES vs. BMS
SAT 0.5% vs. 0.5%
LST 0.4% vs. 0.3%
VLST 0.9% vs. 0.6%
18 Deﬁnite: ACSangio
Possible: all SCD and MI
attributable to the
target vessel
Deﬁnite: DES 1.4% vs. BMS 0.8%
Deﬁnitepossible: DES 2.6% vs. 1.3%
14–41 ACSangio, MI in stented
territory
SAT: PES 0.5% vs. BMS 0.5%
LSTVLST: PES 0.5% vs. BMS 0.06%
48 According to deﬁnitions in
individual trial
protocols
SES vs. BMS
SAT 0.5% vs. 0.1%
LST 0.5% vs. 0.1%
VLST 0.6% vs. 0%
PES vs. BMS
SAT 0.5% vs. 0.6%
LST 0.2% vs. 0.1%
VLST 0.7% vs. 0.2%
12–36 ACSangio DES vs. BMS
0.5% vs. 0%
SES vs. BMS
0.36% vs. 0%
PES vs. BMS
0.59% vs. 0%
ncluding 10 randomized studies. J Am Coll Cardiol 2005;45:954–9. †Kastrati A, Dibra A, Eberle S, et
is of randomized trials. JAMA 2005;294:819–25.
acetylsalicylic acid; bifurc bifurcation; BASKET-LATE Basel Stent Kosten Effiktivitats Trial-Late
VEF left ventricular ejection fraction; MImyocardial infarction; PCI percutaneous coronary
hrombosis; SCD sudden cardiac death; SES sirolimus-eluting stent(s); ST stent thrombosis;nalys
d
ths)
ths)
ths)
ths)
)
ths)
nalysis i
a-analys
; ASA
bosis; L
stent tear, often in association with cessation of DAT, suggest
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586erhaps that even further prolongation of treatment might
e appropriate (21–24). Additionally, there is compelling
vidence for clopidogrel or ASA resistance as strong pre-
ictors for DES as well as BMS thrombosis (20).
uonamici et al. (15) investigated clopidogrel-induced
latelet inhibition in patients after DES implantation. The
ncidence of subacute and late ST among nonresponders
as 8.6%, compared with 2.3% among responders (HR:
.08, p  0.009). Although higher clopidogrel dosing (150
g daily) might have theoretical advantages in these situa-
ions, the risk-to-benefit ratio of this treatment strategy is
nknown (24). Triple antiplatelet therapy with ASA, a
hienopyridine, and cilostazol has been associated with a
educed rate of subacute BMS thrombosis compared with
SA/thienopyridine (25), although the regimen’s role in
he DES era is undetermined.
he Kounis Syndrome:
ole in Late/Very Late ST?
he Kounis, or hypersensitivity-associated acute coronary,
yndrome (26) was first described 18 years ago as the concur-
ence of acute coronary syndrome with allergic, hypersensitiv-
ty, anaphylactic, or anaphylactoid reactions. Potential culprits
esponsible for this phenomenon include: arachidonic acid
etabolites such as leukotrienes and thromboxane, proteolytic
nzymes such as chymase and tryptase, histamine, cytokines,
Table 2. Reported Rates of ST: Patient Registries
Study (Ref. #) n
Stent
Type
Antiplatelet
Medication and
Duration
Follow-
Duratio
(Month
Ong et al.* 2,512 BMS (20%)
SES (40%)
PES (40%)
ASATP (1 month) 1
Lemos et al. (5) 958 BMS (53%)
SES (47%)
ASATP (1 month) 12
Jensen et al. (8) 12,395 DES (27%)
SES (73%)
ASATP (3–12 months) 5
Iakovou et al.† 2,229 SES (48%)
PES (52%)
ASATP (2–6 months) 9
Williams et al.‡ 6,906 BMS (6%)
SES (56%)
PES (38%)
ASATP 12
Ong et al.§ 2,006 SES (51%)
PES (49%)
ASATP (2–6 months) 12 
Kuchulakanti et al. (21) 2,974 SES (72%)
PES (28%)
ASATP (6 month) 12
Daemen et al. (11) 8,146 SES (47%)
PES (53%)
ASATP (2–6 months) 20
*Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic ste
†Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, andoutcomeof thrombosis after succ
of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. R
PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-elut
Abbreviations as in Table 1.nd chemokines. Additionally, inflammatory cells such as Aacrophages, T-lymphocytes, and mast cells are also contrib-
tory. Mast cells usually exist within the atherosclerotic lesion
nd release massive quantities of inflammation mediators such
s cytokines and chemokines, leading to platelet activation.
latelets play a critical role in the inflammatory pathways. Two
ariants of the Kounis syndrome have been described recently.
ype I includes patients with normal coronary arteries and
epresents a manifestation of endothelial dysfunction, whereas
he Type II variant describes individuals with quiescent preex-
sting atheromatous disease (27).
Hypersensitivity might be an under-recognized compo-
ent of ST, especially in delayed cases. All 3 components of
ES can potentially elicit hypersensitivity responses in-
olved in the Kounis syndrome (28). Patients with positive
llergic patch-test reactions to the metallic strut compo-
ents nickel and molybdenum seem to have increased rates
f in-stent thrombosis (29). Autopsy-confirmed inflamma-
ory cell infiltrates—namely lymphocytes, plasma cells, mac-
ophages, and eosinophils—permeate all 3 vascular wall
ayers; comprising a histopathological landscape reminiscent
f that observed in the Kounis syndrome (20).
Virmani et al. (30) described a case of local hypersensi-
ivity reaction in a patient suffering DES very late ST 18
onths after DES implantation. Autopsy findings revealed
xtensive vasculitis of the intima, media, and adventitia,
onsisting predominantly of lymphocytes and eosinophils.
ST Definition ST Rate
eﬁnite: angio
ossible: SCD or MI attributable to
the target vessel
Deﬁnite: BMS 0.8%, SES 1%, PES 1%
Possible: BMS 1.4%, SES, 1.5%,
PES 1.6%
T: angio SES 0.4% vs. BMS 1.6%
RC: deﬁniteprobablepossible Overall ST: 1.8% DES, 2.15% BMS
CSangio, SCD or MI after successful PCI
not due to another coronary lesion
SAT: 0.6%
LST: 0.7%
eﬁnite: angio
ossible: SCD or MI attributable to the
target vessel
Deﬁniteprobable: BMS 0.8%,
SES 0.5%, PES 0.8%
CSangio LST: 0.25%
VLST: 0.15%
utopsy or angio (ACS if 30 days
after PCI)
SAT: 0.84%
LST: 0.27%
CSangio SAT: 1.1%
LST: 0.3%
VLST: 0.4%
sion after bare-metal, sirolimus, or paclitaxel stent implantation. J AmColl Cardiol 2005;45:947–53.
plantation of drug-eluting stents. JAMA2005;293:2126–30.‡WilliamsD, Abbott J, Kip K. Outcomes
f theDEScover Registry. Circulation 2006;114:2154–62.§OngAT,McFadden EP, Regar E, de Jaegere
ts. J Am Coll Cardiol 2005;45:2088–92.Up
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587tented segment, with evidence of stent malapposition and
hick fibrin thrombus between the stent and arterial wall.
he polymer matrix was thus postulated to be the allergenic
ulprit, because sirolimus is nondetectable beyond 60 days.
Data derived from the FDA’s Manufacturer And User
evice Experience (MAUDE) Center (31) and the Re-
earch on Adverse Drug/device events And Reports (RA-
AR) (31,32) project have registered several hundred cases
f hypersensitivity reactions in conjunction with DES im-
lantation. They designated 17 cases as probably or defi-
itely DES-related; of these, 4 developed fatal ST at 4, 5,
8, and 18 months after implantation, respectively. These
eactions included rash, itching, hives, dyspnea, fever, atyp-
cal chest pain, hypertension, hypotension, arthralgia, joint
welling, and anaphylaxis.
Although MAUDE and RADAR data might be skewed
y under-reporting, hypersensitivity to DES is now re-
arded as a true clinical entity with obvious serious impli-
ations. Health care providers are encouraged to submit
etailed adverse event reports to the manufacturer as well as
he FDA (33). The proportion of allergic reactions in the
ver 5 million DES implantations is well below the ex-
ected 4% for allergy from drugs alone. However, coronary
Table 3. Potential Risk Factors for Drug-Eluting Stent Thrombosis
Patient factors
Diabetes mellitus
Chronic renal insufﬁciency
Low left ventricular ejection fraction
Acute myocardial infarction
Hypersensitivity to metal
Low or nonresponder to dual antiplatelet therapy
Early discontinuation of dual antiplatelet therapy
Lesion factors
Necrotic core lesion
Ostial lesion
Bifurcation lesion
Long lesion
Small vessel lesion
Device factors
Durable polymer
Uneven drug distribution
Incomplete drug release
Drug cytotoxicity
Uneven expansion
Foreign body
Incomplete strut coverage
Procedure factors
Overlapping stents
Multiple stents
Crush stenting
Stent malapposition or underexpansion
In-stent restenosis
Untreated residual dissection/thrombusvents associated with hypersensitivity reactions are notommon and are dependent on allergen concentration,
oute and rate of allergen entrance into the circulation, and
agnitude of the initial allergic response. Moreover, the
rea and localization of antibody–antigen reaction as well as
he patient’s sensitivity tolerance and pre-existent comor-
idities are further determinants of ultimate clinical mani-
estations (34). As determined by the aforementioned con-
itions, patient-specific threshold inflammatory cell burdens
ikely exist, above which smooth muscle contraction and
laque erosion or rupture might occur (35).
Several reports have implicated antineoplastic agents,
uch as those incorporated into DES, in hypersensitivity
eactions (36–41). In 1 recent series (36), up to 42% of
atients receiving systemic paclitaxel chemotherapy experi-
nced some form of hypersensitivity reaction; and up to 2%
eveloped serious allergic sequelae. Studies have linked this
ompound in both Types I and II variants of the Kounis
yndrome (37–39). In another report (40), a patient expe-
ienced anaphylactic reaction during DES implantation.
pon DES deployment, the patient developed an erythem-
tous rash, accompanied by hypotension, coronary spasm,
nd thrombosis. Delayed severe multivessel coronary arterial
pasm and aborted sudden death have also been observed
fter DES implantation (41).
Hypersensitivity reactions have likewise been reported
ith polymers; these allergic responses are predominately
ype-IV reactions, involving low molecular weight haptens.
acrophages, giant cells, tissue damage, and fibrosis are
een during subcutaneous implantation of poly-n-
utylmethacrylate, which is a component of bone cement
nd the polymer coating of sirolimus-eluting stents (42).
urthermore, the polyethylene-vinyl acetate component of
he co-polymer induces inflammatory reaction in 25% of
abbits when used as an antigen delivery matrix (43).
The majority of intracoronary stents are constructed from
16L stainless steel, which contains nickel, chromium, and
olybdenum. Nickel hypersensitivity occurs in up to 17.2%
Table 4. Academic Research Consortium Definition of ST
Timing of ST after stent implantation (combined acute and subacute are also
considered early ST)
Acute: between 0 and 24 h
Subacute: between 24 h and 30 days
Late: between 30 days and 1 year
Very late: after 1 year
Deﬁnite ST
Angiographic conﬁrmation: intrastent thrombus (or within 5 mm of
stent edge)
Target vessel occlusion
Probable ST
Acute MI in the target vessel territory
Possible ST
Any unexplained death in a patient with prior DES implantationAbbreviations as in Table 1.
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588f the population and is the most frequent cause of allergic
ontact dermatitis (44). In patients undergoing percutane-
us atrial septal defect and patent foramen ovale closure,
ickel allergy can result in a cadre of systemic symptom-
tology including chest discomfort, palpitations, and mi-
raine headache with or without aura (45). It is postulated
hat local allergic reaction to the implanted device could
licit platelet adhesion and activation, resulting in coronary
r cerebrovascular thromboembolism (46). When nickel
llergy is confirmed by patch testing, systemic allergic
eactions to nitinol have necessitated the removal of these
ntracardiac devices (47,48). Delayed hypersensitivity reac-
ions to nickel and molybdenum have been implicated as
riggers for initiation of ST (29); the incidence of nickel
llergy after initial stent deployment has been estimated at
.2% (49). Presently, there is insufficient evidence for
ecommendation of widespread screening for nickel allergy
or all potential DES patients. Nonetheless, given the
revalence of this metallic hypersensitivity, future research is
eeded to address the potential necessity for assessment of
his and other component hypersensitivities before contem-
lation of stent implantation.
Contact allergy to gold has been associated with resteno-
is of gold-plated stents; these devices have since been
bandoned (50). In contrast, the Titan stent (Hexacath
orporation, Pune, India), a stainless steel stent coated with
itanium-nitride oxide (TINOX) can prevent discharge of
ickel, chromium, and molybdenum and seems promising
n the reduction of local allergy and inflammation (51).
Figure 1. Macroscopic Images of Porcine Coronary Luminal Surfaces After
All drug-eluting stent (DES) segments revealed mild-to-severe mural thrombi a
These features are particularly prominent in the central segments of DES overl
neointima, with virtual strut non-visualization. Reprinted, with permission, from
descending artery; RCA  right coronary artery; PES  paclitaxel-eluting stentlthough the concurrence of acute coronary syndrome with iypersensitivity reactions has been long-established (26),
he specific association with hypersensitivity to DES com-
onents is unproven (52–54).
Furthermore, both ASA and clopidogrel, crucial therapy
or DES patients, are themselves known antigenic sub-
tances (55). ASA hypersensitivity has been well-described,
nd prior published data have substantiated successful de-
ensitization as a safe and beneficial strategy in the appro-
riate individual (56). The incidence of clopidogrel hyper-
ensitivity is estimated at 4% (57). As with many other
llergens, the spectrum of clinical manifestations ranges
rom mild rash to potentially fatal anaphylaxis. Presently, no
erologic assay for clopidogrel allergy is available; hence,
iagnosis can only be made clinically, after exposure. Al-
hough alternative therapy with ticlopidine can be consid-
red in such cases, this drug’s associated side-effects, espe-
ially hematologic, make it a less-attractive agent.
Von Tiehl et al. (58) assessed the safety and efficacy of
lopidogrel desensitization in 24 consecutive patients. Ti-
ration was gradually escalated until the targeted daily dose
f 75 mg was achieved. Most (n  20) were performed in
he outpatient setting, and follow-up evaluations were
onducted at 2 to 4 weeks and 6 months after initiation.
hey observed persistent pruritis in 1 patient, whereas the
est remained asymptomatic. The authors thus concluded
hat clopidogrel desensitization is safe, effective, and sus-
ained and recommend consideration of this strategy in
ppropriate patients. It should be noted, however, that
atients with severe allergic reactions to clopidogrel, includ-
apping DES and BMS Implantation
nsparently visible stent struts, consistent with absent to sparse neointima.
nversely, bare-metal stent (BMS)-treated vessels developed robust, white
yala et al. (19). Cx  circumﬂex coronary artery; LAD  left anteriorOverl
nd tra
ap. Co
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589naphylaxis, and respiratory compromise, were excluded
rom this study. Thus, the applicability of their findings to
uch a high-risk subgroup remains unknown.
The course of hypersensitivity is divided into 2 phases:
mmediate (either early or acute) and late. The immediate
eaction occurs within 1 h after antigenic exposure and is
riven by cross-linking of antigen-specific immunoglobulin
(IgE) bound to the surface of resident mast cells. Acute
T occurs within the same time frame as immediate
ypersensitivity (within 24 h). Additionally, both patho-
hysiologic processes demonstrate similar patterns of in-
ammatory cell infiltration (55).
The late phase reaction is, in many respects, a conse-
Figure 2. High Magnification (200) Microscopic Images of Hematoxylin-E
(A) Bare-metal stent (BMS) segments exhibited well-healed, thick ﬁbrocellular n
(DES) (designated PES for paclitaxel-eluting stent), the neointima is attenuated
round mononuclear cells (inﬂammatory white blood cells; white arrows) as w
and hemorrhagic in appearance (*), and inﬂammatory cell inﬁltrations (white
were markedly ampliﬁed in the DES overlap segments. Reprinted, with permisuence of the initial mast cell-driven events and occurs 12 to T4 h after index antigenic exposure (55). The pathophysi-
logy is characterized by recruitment of inflammatory cells
ncluding eosinophils, basophils, T-lymphocytes, neutro-
hils, and macrophages to the site of hypersensitivity and
nflammation. The process is facilitated by chemokines such
s eotaxins-1 and -2, and RANTES (regulation upon
ctivation normal T-cell expressed and secreted). Addition-
lly, monocyte chemoattractant proteins-3 and -4 as well as
acrophage inflammatory protein 1 further contribute to
ugmentation of the cascade. These agents synergistically
romote the expression of adhesion molecules on the
ascular endothelial surface and provide a chemotactic
radient for cells recruited in the late-phase reaction (59).
tained Porcine Coronary Sections
ima, completely covered with endothelial-like cells. For (B) drug-eluting stent
thrombus and ﬁbrinoid deposits juxtaposed to stent struts. Several large
hrombus (black arrows) formations were observed. The media was necrotic
s) were present in DES segments. As in Figure 1, the inﬂammatory changes
rom Pendyala et al. (19).osin S
eoint
, with
ell as t
arrowhe acute-phase reaction, therefore, is additionally essential
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590or the development and propagation of the late-phase
eaction as well as the subsequent chronic hypersensitivity
nflammation (55).
Thus, potential antigens for the susceptible DES patient
an include the stent metal, polymer, antiproliferative drug
oating, ASA, or clopidogrel. Hypersensitivity and inflam-
ation can be initiated by cross-bridging of culprit antigen
ith corresponding receptor-bound IgE antibodies on the
asophil or mast cell surface. Of the total 500,000 to
,000,000 immunoglobulin (Ig)E antibodies on the cell
urface, a threshold number of bridged IgEs (usually
2,000) is required for cellular degranulation and mediator
elease (60). For the DES patient, the critical number of
ridges is potentially achievable by more than 1 non–cross-
eactive antigen and its corresponding IgE antibody (61).
Clinical data indicate that patients simultaneously ex-
osed to several antigens experience more symptoms than
ono-sensitized individuals (61). A recent study revealed
hat IgE antibodies with different specificities can elicit an
dditive effect; likewise, simultaneous exposure to sub-
hreshold quantities of multiple antigens can synergistically
rigger mediator release (62). This finding suggests that
onsideration for desensitization in the DES patient might
ecessitate inclusion of all DES components as well as ASA
nd clopidogrel.
Platelets play a significant role in the development of
hrombosis and inflammation through cytokine secretion
nd subsequent interaction with leukocytes and endothelial
Figure 3. Pathophysiology of Drug-Eluting Stent Thrombosis
Many factors, including impaired neointimal formation, technical issues, possib
vasomotion, patient characteristics, and adjunct pharmacology, all potentially c
sis. Solid arrows  promotional factors. Dashed arrows with question mark
adenosine diphosphate; Ig  immunoglobulin.ells. Antiplatelet agents such as ASA and clopidogrel (a ipecific antagonist of the platelet P2Y12 ADP-receptor)
educe the levels of the transcription factor nuclear factor
appaB (NF-kappaB), C-reactive protein, and soluble
D40 ligand. Furthermore, these agents also attenuate
-selectin concentrations and platelet-leukocyte aggrega-
ion (63). The pathophysiologic mechanism of DES ST,
ith postulated contribution from the Kounis syndrome, is
utlined in Figure 3.
Mast cells are almost ubiquitous within the atheroscle-
otic lesion. Kounis syndrome is associated with mast cell
ctivation, involving interrelated and interacting inflamma-
ory cells including macrophages and T-lymphocytes; plate-
et activation and release of various inflammatory mediators
uch as cytokines and chemokines are also critical compo-
ents of the phenomenon. Therefore, the crucial benefits of
AT after DES cannot be overemphasized; these agents
ecrease not only the propensity for thrombosis but likely
lso the Kounis-associated inflammatory response (64).
hronic Allergic Inflammation
rug release kinetics from DES polymers is a complex
henomenon dependent upon multiple factors. The rate
aries with the type of polymer, layering, and drug/polymer
ormulation ratio. The rapidity of dissipation is further
nfluenced by the overcoat dose and total load densities (63).
mportant determinants for tissue drug accumulation in-
lude drug physicochemical properties, distribution of drug
ersensitivity to drug-eluting stent components (Kounis-associated), impaired
ute to and modify platelet activity, the major determinant of stent thrombo-
ossible promotional factors. Crossed arrows  inhibitory factors. ADP le hyp
ontrib
s  pn the arterial wall, rate and duration of release, endothelial
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591unction, as well as overall health of the arterial wall (63).
he DES drug release is characterized by an initial rapid
hase followed by sustained slow dissipation (64). Li-
ophilic drugs are released slowly, allowing for higher
oncentrations in the intima (65). Conversely, hydrophilic
rugs demonstrate faster elution into the circulation and
equire greater amounts with shorter durations of delivery to
chieve optimal local levels (66). However, in human
therosclerotic intima, drug release characteristics have
emonstrated considerable variability.
Drug release kinetics, levels of insulting allergens, and
resence of drug-reactive lymphocytes all likely contribute
o the timing and type of hypersensitivity reactions; these
an include: immediate (type I), antibody-mediated cyto-
oxic (type II), immune complex-mediated (type III), and
elayed hypersensitivity (type IV) reactions (67). Atopic
atients might experience recurrent reactions even after
ears of antigen avoidance (68), owing to high concentra-
ions of drug-specific lymphocytes. Although the eluted
rug and polymer components of DES dissolve over time,
he stent itself presents a persistent antigenic stress to the
usceptible patient. This possible mechanism is underscored
y demonstration of immune cellular and extracellular
atrix findings characteristic of chronic allergic inflamma-
ory changes in both human and animal models of ST.
ecommendations for Prevention and
iagnosis of DES ST
he FDA has issued, on the basis of an expert panel
estimony, guidelines for prevention of DES ST (4). Similar
ecommendations were echoed in the joint advisory from
he American Heart Association, American College of
ardiology, Society for Cardiovascular Angiography and
nterventions, American College of Surgeons, and Ameri-
an Dental Association, with representation from the
merican College of Physicians (69). Although no strategy
uarantees against ST, these measures likely enhance the
afety profile of these devices.
Before stent deployment, patients should be thoroughly
valuated for risk of noncompliance or inability to comply
ith prolonged DAT. These include: upcoming surgeries,
nancial challenges to prolonged clopidogrel therapy, or
oor compliance; DES should be avoided in these individ-
als. Consideration should be made for platelet inhibition
ssays to ASA and/or clopidogrel in appropriate stent
mplantation candidates.
Adherence to “on-label” indications for DES use can help
o minimize the risks of ST; these indications include: use in
ative coronaries with diameters from 2.5 to 3.5 mm;
voidance of bifurcation stents, overlapping stents, multiple
tents, or long stents. Consider intravascular ultrasound
nterrogation to optimize stent symmetry, apposition, and iizing. Providers need to thoroughly educate DES patients
n the indications of DAT, in particular, strict adherence to
DA recommendations as well as the serious potential
onsequences of premature therapy termination.
Surgery or invasive procedures should be postponed until
ompletion of the minimal recommended DAT duration. If
uch procedures are unavoidable during the first year after
ES implantation, consideration should be given to DAT
r at least ASA continuation, if at all possible. DAT should
e resumed as promptly as deemed safe surgically. All
roposed modifications to DAT should be fully discussed
ith the patient’s cardiologist.
DES ST is usually quite dramatic and unambiguous in
resentation, and all health care providers should be well-
ersed and vigilant in the diagnosis. For any stent patient
resenting with acute coronary syndrome, especially MI, a
ow threshold for urgent coronary angiography/possible
ntervention should be exercised. Furthermore, elucidation
f ST mechanism (e.g., incomplete stent expansion, residual
issection) with intravascular ultrasound interrogation is
ncouraged in most cases of DES thrombosis. Moreover,
T should be strongly considered in any unexplained death
n a DES patient. These recommendations are summarized
Table 5. Suggestions for Prevention and Diagnosis of DES ST
Prevention
Avoid overlapping stents and other “off-label” indications.
Intravascular ultrasound assessment to ensure full and symmetric stent
expansion and wall apposition as well as absence of thrombus or
dissection.
Avoid DES in individuals at risk of noncompliance or inability to comply with
prolonged dual antiplatelet therapy (e.g., upcoming invasive procedures,
ﬁnancial challenges, or history of medical noncompliance).
If invasive procedure or surgery is unavoidable within 1 year after DES
implantation, consideration should be given to continuation of dual
antiplatelet therapy; any antiplatelet alterations should be discussed with
the patient’s cardiologist.
For DES patients undergoing invasive or surgical procedures mandating
thienopyridine discontinuation, ASA should be continued if at all feasible.
Thienopyridine should be re-initiated as soon as possible after procedure.
Strict adherence to FDA antiplatelet therapy recommendations, with
consideration for additional prolongation in high-risk anatomies and
individuals.
Consideration in selected individuals for platelet function assays to assess for
ASA or clopidogrel resistance.
Health care providers should more thoroughly educate patients regarding the
indications of dual antiplatelet therapy as well as the risks of premature
termination.
Diagnosis
Consider urgent coronary angiography/possible intervention for any stent
patient presenting with acute coronary syndrome, especially MI.
Consider intravascular ultrasound interrogation in all cases of DES ST, to
elucidate mechanism (e.g., incomplete stent expansion, residual dissection).
Suspect ST in any unexplained death in a DES patient.
Data is based on information in references 4 and 69.
Abbreviations as in Table 1.n Table 5.
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592onclusions and Future Directions
ith the ever-increasing prevalence of DES use, continued
esearch into thorough understanding of the complex mech-
nisms of ST is paramount. Although hypersensitivity/
llergic reactions are now recognized as key components of
T, the incidence, especially of subclinical cases, is likely
nder-reported. Before consideration for DES implanta-
ion, a thorough atopic history should be sought, with
pecific attention to previous Kounis syndrome or other
llergic reactions. In appropriate patients, pre-PCI evalua-
ion with patch-testing, antibody testing, macrophage and
-cell activation studies, with subsequent desensitization
trategies might be considered. Post-procedural monitoring
f inflammatory mediator levels as well as use of corticoste-
oids and mast cell stabilizers are potential topics for future
nvestigations. Some of the aforementioned recommenda-
ions have recently been incorporated into current protocols
52).
In conclusion, the Kounis syndrome, as a possible man-
festation of hypersensitivity to stent components or anti-
latelet agents, might play a key role in the mechanism of
ES thrombosis. Recent experimental data have reported
ttenuation of allergic and thrombotic events through treat-
ent with corticosteroids and other mast cell stabilizing
gents (70). Accordingly, we have proposed impregnation of
uch agents as a novel DES polymer matrix (71). Incorpo-
ation of anti-inflammatory, antiallergic, and/or antiplatelet
gents might represent a promising paradigm shift from
fficacy to safety in future DES designs.
eprint requests and correspondence: Dr. Jack P. Chen, 5670
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